Hepatotoxins

Agile Therapeutics to Participate in Virtual Fireside Chat as Part of the 2021 RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Wednesday, May 12, 2021
Sex hormones, Drugs, Organic compounds, Estranes, Hormonal contraception, Hepatotoxins, Prolactin releasers, Phenols, XC2, Levonorgestrel, Estradiol, Ethinylestradiol

b"PRINCETON, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women\xe2\x80\x99s healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a virtual fireside chat as part of the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 1:20 p.m. ET.\nThe fireside chat will be webcast live and can be accessed in the Events and Presentations section of the Investor Relations page at https://ir.agiletherapeutics.com/events-and-presentations/ , or by clicking here: https://event.on24.com/wcc/r/3173531/F391B23E756682EFEFE4952267784F45\nThe webcast will be archived on the Agile Therapeutics website for 30 days following the event.\nAgile Therapeutics\xc2\xa0is a forward-looking women's healthcare company dedicated to fulfilling the unmet health needs of today\xe2\x80\x99s women.\xc2\xa0Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.\xc2\xa0Our initial product, Twirla\xc2\xae, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive.

Key Points: 
  • b"PRINCETON, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women\xe2\x80\x99s healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a virtual fireside chat as part of the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 1:20 p.m. ET.\nThe fireside chat will be webcast live and can be accessed in the Events and Presentations section of the Investor Relations page at https://ir.agiletherapeutics.com/events-and-presentations/ , or by clicking here: https://event.on24.com/wcc/r/3173531/F391B23E756682EFEFE4952267784F45\nThe webcast will be archived on the Agile Therapeutics website for 30 days following the event.\nAgile Therapeutics\xc2\xa0is a forward-looking women's healthcare company dedicated to fulfilling the unmet health needs of today\xe2\x80\x99s women.\xc2\xa0Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.\xc2\xa0Our initial product, Twirla\xc2\xae, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive.
  • Twirla is based on our proprietary transdermal patch technology, called Skinfusion\xc2\xae, which is designed to allow drug delivery through the skin.
  • For more information, please visit the company website at www.agiletherapeutics.com .
  • The Company may occasionally disseminate material, nonpublic information on the Company\xe2\x80\x99s website.\n"

Hyloris Announces Extension of Footprint of Maxigesic® IV into South America

Retrieved on: 
Thursday, May 6, 2021
Drugs, Hepatotoxins, Analgesics, Combination analgesics, Acetanilides, Paracetamol, Pesticides, Ibuprofen, Opioid, Oxycodone/ibuprofen, Hydrocodone/ibuprofen

Maxigesic IV is a unique combination of 1000mg paracetamol with 300mg ibuprofen solution for infusion for use post-operatively.

Key Points: 
  • Maxigesic IV is a unique combination of 1000mg paracetamol with 300mg ibuprofen solution for infusion for use post-operatively.
  • Moreover, the superior analgesic effect of Maxigesic IV was supported by a range of secondary endpoints, including reduced opioid consumption compared to the paracetamol IV and ibuprofen IV treatment groups (P
  • Hyloris currently has two partnered, commercial-stage products: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic\xc2\xae IV, a non-opioid post-operative pain treatment.
  • The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.\n4 Maxigesic IV Phase 3 study.

Assertio Holdings, Inc. Partners with Cove, a Leading Migraine Telemedicine Platform, To Launch Direct to Patient Digital Campaign to Increase Accessibility of CAMBIA® (diclofenac potassium) and SPRIX® (ketorolac tromethamine)

Retrieved on: 
Wednesday, May 5, 2021
Medical specialties, Hepatotoxins, Nonsteroidal anti-inflammatory drugs, Chloroarenes, Diclofenac, Clinical medicine, Health care, Jaundice, Hepatitis, Liver, Cambia

Different\nformulations of oral diclofenac (e.g., CAMBIA, diclofenac sodium enteric-coated tablets, diclofenac sodium\neven if the milligram strength is the same.

Key Points: 
  • Different\nformulations of oral diclofenac (e.g., CAMBIA, diclofenac sodium enteric-coated tablets, diclofenac sodium\neven if the milligram strength is the same.
  • Postmarketing\nsurveillance has reported cases of severe hepatic reactions, including liver necrosis, jaundice, fulminant\nhepatitis with and without jaundice, and liver failure.
  • If CAMBIA is used in patients with severe heart\nfailure, monitor patients for signs of worsening heart failure.\nnecrosis and other renal injury.
  • These forward-looking statements relate to, among other things, future events or the future performance or operations of Assertio.

Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of Bacterial Infections, in the United States

Retrieved on: 
Tuesday, May 4, 2021
Infectious diseases, Biotechnology, Pharmaceutical, Health, Chemical compounds, Chemistry, Organic compounds, Hepatotoxins, Statins, Lactones, Macrolide antibiotics, Ethers, Erythromycin, Simvastatin, Lovastatin, Diarrhea, Erythromycin Tablets, Teva, ERYTHROMYCIN TABLETS, TEVA

If you are unsure, ask your doctor if you are taking any of these medications.\nErythromycin tablets should not be taken together with certain statins including lovastatin or simvastatin.

Key Points: 
  • If you are unsure, ask your doctor if you are taking any of these medications.\nErythromycin tablets should not be taken together with certain statins including lovastatin or simvastatin.
  • Erythromycin tablets should be avoided in patients with heart or heart rate problems, and/or are taking medications to treat these conditions.
  • The condition can range in severity from mild diarrhea to fatal inflammation of the colon.\nErythromycin tablets should only be used to treat bacterial infections.
  • Although it is common to feel better early in the course of taking erythromycin tablets, the medication should be taken exactly as directed.

PLx Pharma Inc. to Discuss 2021 First Quarter Financial Results on May 14, 2021 Conference Call and Provide Business Update

Retrieved on: 
Monday, May 3, 2021
Drugs, Hepatotoxins, Pharma, Aspirin

b"www.plxpharma.com under the \xe2\x80\x98Investor Relations\xe2\x80\x99 section.\nA replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International).

Key Points: 
  • b"www.plxpharma.com under the \xe2\x80\x98Investor Relations\xe2\x80\x99 section.\nA replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International).
  • The conference ID for the replay is 6238639.
  • It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.\nPLx Pharma Inc. is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard\xe2\x84\xa2 drug delivery platform to provide more effective and safer products.
  • The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract.

VYNE Therapeutics to Report First Quarter 2021 Financial Results on May 6, 2021

Retrieved on: 
Wednesday, April 28, 2021
Hepatotoxins, Anti-acne preparations, Tetracycline antibiotics, Minocycline, Triketones, XC2, Medication package insert, Drugs, Health sciences, Health

b'A replay of the call will be archived on the Company\xe2\x80\x99s website at www.vynetherapeutics.com after the conference call.\nVYNE\xe2\x80\x99s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.\nWith expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST\xe2\x84\xa2), and has received FDA approval for AMZEEQ\xc2\xae (minocycline) topical foam, 4%, the world\xe2\x80\x99s first topical minocycline, and for ZILXI\xc2\xae (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea.\xc2\xa0For more information about our approved products, please see AMZEEQ\xe2\x80\x99s Full Prescribing Information at AMZEEQ.com and ZILXI\xe2\x80\x99s Full Prescribing Information at ZILXI.com .\nFor more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter.

Key Points: 
  • b'A replay of the call will be archived on the Company\xe2\x80\x99s website at www.vynetherapeutics.com after the conference call.\nVYNE\xe2\x80\x99s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.\nWith expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST\xe2\x84\xa2), and has received FDA approval for AMZEEQ\xc2\xae (minocycline) topical foam, 4%, the world\xe2\x80\x99s first topical minocycline, and for ZILXI\xc2\xae (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea.\xc2\xa0For more information about our approved products, please see AMZEEQ\xe2\x80\x99s Full Prescribing Information at AMZEEQ.com and ZILXI\xe2\x80\x99s Full Prescribing Information at ZILXI.com .\nFor more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter.
  • VYNE may use its website to comply with its disclosure obligations under Regulation FD.
  • Therefore, investors should monitor VYNE\xe2\x80\x99s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.\n'

Hyloris Announces Major Commercial Partnership in the U.S. for Maxigesic® IV

Retrieved on: 
Wednesday, April 28, 2021
Drugs, Hepatotoxins, Analgesics, Combination analgesics, Acetanilides, Paracetamol, Pesticides, Ibuprofen, Opioid, Oxycodone/ibuprofen, Hydrocodone/ibuprofen

Maxigesic IV is a unique combination of 1000mg paracetamol with 300mg ibuprofen solution for infusion for use post-operatively.

Key Points: 
  • Maxigesic IV is a unique combination of 1000mg paracetamol with 300mg ibuprofen solution for infusion for use post-operatively.
  • Moreover, the superior analgesic effect of Maxigesic IV was supported by a range of secondary endpoints, including reduced opioid consumption compared to the paracetamol IV and ibuprofen IV treatment groups (P
  • Hyloris currently has two partnered, commercial-stage products: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic\xc2\xae IV, a non-opioid post-operative pain treatment.
  • The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.\n4 Maxigesic IV Phase 3 exposure study.

Global Ibuprofen Market Size to Grow at 2-3 Percent CAGR by 2023, Says Beroe Inc

Retrieved on: 
Wednesday, April 21, 2021
Hepatotoxins, Analgesics, Ibuprofen, Racemate, Drugs, Chemistry, Physical sciences

b"RALEIGH, N.C., April 21, 2021 /PRNewswire/ -- In 2019, the Ibuprofen market size was estimated at around $573 million.

Key Points: 
  • b"RALEIGH, N.C., April 21, 2021 /PRNewswire/ -- In 2019, the Ibuprofen market size was estimated at around $573 million.
  • Even though scoring low in demand capability, developing nations are leading the supplier market, becoming global Ibuprofen exporters.
  • Whereas India exports around 493 tons of Ibuprofen API to the UK and Ireland.\nIndia and the U.S. are the leading supply centers for Ibuprofen API.
  • The high cost of raw material in 2020 has led to an elevation in the price of Ibuprofen across the global ibuprofen market.

Global Ibuprofen Market Size to Grow at 2-3 Percent CAGR by 2023, Says Beroe Inc

Retrieved on: 
Wednesday, April 21, 2021
Hepatotoxins, Analgesics, Ibuprofen, Racemate, Drugs, Chemistry, Physical sciences

b"RALEIGH, N.C., April 21, 2021 /PRNewswire/ -- In 2019, the Ibuprofen market size was estimated at around $573 million.

Key Points: 
  • b"RALEIGH, N.C., April 21, 2021 /PRNewswire/ -- In 2019, the Ibuprofen market size was estimated at around $573 million.
  • Even though scoring low in demand capability, developing nations are leading the supplier market, becoming global Ibuprofen exporters.
  • Whereas India exports around 493 tons of Ibuprofen API to the UK and Ireland.\nIndia and the U.S. are the leading supply centers for Ibuprofen API.
  • The high cost of raw material in 2020 has led to an elevation in the price of Ibuprofen across the global ibuprofen market.

Precision Medicine Company adyn Raises $2.5M Seed Funding for Personalized Birth Control

Retrieved on: 
Monday, April 19, 2021
Women, Biotechnology, Pharmaceutical, Medical Supplies, Health, Genetics, Consumer, Other Health, Hepatotoxins, Birth control, Women's health, Medical prescription, Fertility, Hormonal contraception, Health

b'adyn , a precision medicine company, announced today that it has closed a $2.5 million seed round of funding.

Key Points: 
  • b'adyn , a precision medicine company, announced today that it has closed a $2.5 million seed round of funding.
  • Today, the standard of care for hormonal birth control prescription is simply trial and error, and the average time spent on contraceptive counseling is 12.9 minutes.
  • Dr. Ruzzo\xe2\x80\x99s expertise in precision medicine will introduce a new standard of care for birth control and close gaps caused by historic inequity in medical research.
  • Founded in 2019, adyn provides medically actionable scientific insights and empowers individuals to proactively optimize their health\xe2\x80\x94from birth control, to fertility, and beyond.